During the past decade, Shinshu University Hospital conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 20 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 18 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shinshu University Hospital" #1 sponsor was "Pfizer" with 7 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Amgen" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Actelion" with 4 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shinshu University Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Association for Establishment of Ebvidence in Interventions" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Eidos Therapeutics, a BridgeBio company" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Shinshu University Hospital" are "Psoriasis" (5 trials), "Heart Failure" (3 trials), "Duchenne Muscular Dystrophy" (2 trials), "Epithelial Ovarian Cancer" (2 trials) and "Macular Edema" (2 trials). Many other conditions were trialed in "Shinshu University Hospital" in a lesser frequency.

Most popular intervention types in "Shinshu University Hospital" are "Drug" (47 trials), "Other" (7 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Faricimab" (3 trials), "Sham Procedure" (3 trials), "Aflibercept" (2 trials) and "Apremilast" (2 trials). Other intervention names were less common.

The vast majority of trials in "Shinshu University Hospital" are 50 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Shinshu University Hospital". undefined are not yet recruiting, 13 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Shinshu University Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Shinshu University Hospital, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".